B
BrainCo develops brain-computer interface technology that decodes neural signals for medical and commercial applications.
$2.8BPre-IPO
Investor undisclosed
A $2.8B pre-IPO round for a Chinese BCI company signals that neural decoding has moved from research curiosity to capital-scale commercialization—likely driven by regulatory clarity in China and real clinical/consumer traction. At this stage and size, they're probably scaling manufacturing, building out clinical evidence for specific indications (motor control, communication), and preparing for public markets. If you're in adjacent neurotech, assistive devices, or even consumer health hardware, watch their go-to-market playbook closely—this validates that the regulatory and reimbursement path exists, even if it's China-first.